Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter multiplatform study

Classification of the antiphospholipid syndrome (APS) relies predominantly on detecting antiphospholipid antibodies (aPLs). Antibodies against a domain I (DI) epitope of anti‐β2glycoprotein I (β2GPI) proved to be pathogenic, but are not included in the current classification criteria.

[1]  J. Gris,et al.  Detection of Anti-Cardiolipin and Anti-β2glycoprotein I Antibodies Differs between Platforms without Influence on Association with Clinical Symptoms , 2019, Thrombosis and Haemostasis.

[2]  K. Devreese,et al.  The clinical value of assays detecting antibodies against domain I of β2-glycoprotein I in the antiphospholipid syndrome. , 2018, Autoimmunity reviews.

[3]  J. Musial,et al.  Identification of high thrombotic risk triple‐positive antiphospholipid syndrome patients is dependent on anti‐cardiolipin and anti‐β2glycoprotein I antibody detection assays , 2018, Journal of thrombosis and haemostasis : JTH.

[4]  A. Tincani,et al.  Beyond thrombosis: Anti-β2GPI domain 1 antibodies identify late pregnancy morbidity in anti-phospholipid syndrome. , 2018, Journal of autoimmunity.

[5]  T. Ortel,et al.  Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.

[6]  W. Chayoua,et al.  The Significance of Antibodies against Domain I of Beta-2 Glycoprotein I in Antiphospholipid Syndrome , 2017, Seminars in Thrombosis and Hemostasis.

[7]  A. Hoxha,et al.  Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome , 2017, Clinical chemistry and laboratory medicine.

[8]  J. Musial,et al.  Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome. , 2017, Thrombosis research.

[9]  M. Laffan,et al.  Pathogenesis and management of antiphospholipid syndrome , 2017, British journal of haematology.

[10]  S. Yasuda,et al.  Significance of fully automated tests for the diagnosis of antiphospholipid syndrome. , 2016, Thrombosis research.

[11]  J. Musial,et al.  Role of anti‐domain 1‐β2glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome , 2016, Journal of thrombosis and haemostasis : JTH.

[12]  M. Khamashta,et al.  Autoantibodies to domain 1 of beta 2 glycoprotein I determined using a novel chemiluminescence immunoassay demonstrate association with thrombosis in patients with antiphospholipid syndrome , 2016, Lupus.

[13]  Fengchun Zhang,et al.  Evaluation of the diagnostic potential of antibodies to beta2-glycoprotein 1 domain 1 in Chinese patients with antiphospholipid syndrome , 2016, Scientific Reports.

[14]  A. Hoxha,et al.  Antibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profiles. , 2015, Thrombosis research.

[15]  P. Simioni,et al.  Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[16]  A. Ruffatti,et al.  Antiphospholipid syndrome: antibodies to Domain 1 of β2‐glycoprotein 1 correctly classify patients at risk , 2015, Journal of thrombosis and haemostasis : JTH.

[17]  A. Tincani,et al.  Clinical Characterization of Antiphospholipid Syndrome by Detection of IgG Antibodies Against β2‐Glycoprotein I Domain 1 and Domain 4/5: Ratio of Anti–Domain 1 to Anti–Domain 4/5 As a Useful New Biomarker for Antiphospholipid Syndrome , 2015, Arthritis & rheumatology.

[18]  Y. Shoenfeld,et al.  Immunoreactivity and avidity of IgG anti-β2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of β2-glycoprotein I , 2015, Immunologic research.

[19]  D. Isenberg,et al.  Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis , 2014, Rheumatology.

[20]  M. Petri,et al.  14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. , 2014, Autoimmunity reviews.

[21]  T. Ortel,et al.  Testing for Antiphospholipid antibodies with Solid Phase Assays: guidance from the SSC of the ISTH , 2014, Journal of thrombosis and haemostasis : JTH.

[22]  M. Mahler,et al.  Role of antiphospholipid score and anti-β2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[23]  D. Roccatello,et al.  Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome , 2013, Thrombosis and Haemostasis.

[24]  K. Devreese,et al.  Differences in sensitivity of two automated assay panels for anticardiolipin and anti beta2glycoprotein I antibodies in the laboratory diagnosis of antiphospholipid syndrome due to the exposure of the domain I epitope of beta2glycoprotein I on the solid phase , 2014 .

[25]  P. D. de Groot,et al.  Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-Beta2-Glycoprotein I IgG ELISAs , 2013, PloS one.

[26]  B. de Laat,et al.  Antibodies against domain I of β2-glycoprotein I: the one and only? , 2012, Lupus.

[27]  K M J Devreese,et al.  Standardization of antiphospholipid antibody assays. Where do we stand? , 2012, Lupus.

[28]  T. Ortel.  Antiphospholipid syndrome: Laboratory testing and diagnostic strategies , 2012, American journal of hematology.

[29]  C. Maas,et al.  Immune responses against domain I of β(2)-glycoprotein I are driven by conformational changes: domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. , 2011, Arthritis and rheumatism.

[30]  Sabino Iliceto,et al.  Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. , 2011, Blood.

[31]  A. Tincani,et al.  Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: a multicentre, case-control study. , 2011, Rheumatology.

[32]  P. D. de Groot,et al.  β2‐Glycoprotein I: evolution, structure and function , 2011, Journal of thrombosis and haemostasis : JTH.

[33]  B. Furie,et al.  β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. , 2011, Blood.

[34]  A. Tincani,et al.  Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their ‘innocent’ profile? , 2010, Annals of the rheumatic diseases.

[35]  P. D. de Groot,et al.  Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. , 2010, Blood.

[36]  S. Iliceto,et al.  Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome , 2010, Journal of thrombosis and haemostasis : JTH.

[37]  P. D. de Groot,et al.  The association between circulating antibodies against domain I of beta2‐glycoprotein I and thrombosis: an international multicenter study , 2009, Journal of thrombosis and haemostasis : JTH.

[38]  D. Isenberg,et al.  In vivo inhibition of antiphospholipid antibody‐induced pathogenicity utilizing the antigenic target peptide domain I of β2‐glycoprotein I: proof of concept , 2009, Journal of thrombosis and haemostasis : JTH.

[39]  P. D. de Groot,et al.  Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. , 2006, Blood.

[40]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[41]  S. Iannaccone.  Meeting Abstracts , 2003, Journal of child neurology.

[42]  D. Sblattero,et al.  Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. , 2005, Blood.

[43]  P. D. de Groot,et al.  IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. , 2005, Blood.

[44]  J. Vermylen,et al.  Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. , 2003, Blood.

[45]  G. M. Iverson,et al.  Use of Single Point Mutations in Domain I of β2-Glycoprotein I to Determine Fine Antigenic Specificity of Antiphospholipid Autoantibodies1 , 2002, The Journal of Immunology.

[46]  E. Harris,et al.  The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.